← All indications
Leukemia, Myeloid, Accelerated Phase
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Drugs by status
Approved for this indication (1)
Phase 3 trials (1)
Phase 2 trials (12)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (48)
- Incyte
- ChemGenex Pharmaceuticals
- Takeda
- Amgen
- Pfizer
- Novartis
- Ariad Pharmaceuticals
- Ascentage Pharma Group Inc.
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Gachon University
- University of Washington
- Inje University
- Johns Hopkins University
- Korea University
- Rutgers University
- Seoul National University
- The Korean Society of Blood and Marrow Transplantation
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- University of Nebraska
- University of Toronto
- Yonsei University
- Chonbuk National University
- Daegu Catholic University
- Dutch Childhood Oncology Group
- Peking University
- University of Chicago
- +18 more